FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2919086883> ?p ?o ?g. }

• W2919086883 endingPage "654" @default.
• W2919086883 startingPage "644" @default.
• W2919086883 abstract "Rheumatoid arthritis (RA) is an autoimmune disease that primarily affects the synovial joints and can lead to bone erosion and cartilage damage. One hallmark of RA is anticitrullinated protein autoantibodies (ACPA) and memory citrulline-specific B-cells, which have been implicated in RA pathogenesis. While depletion of B-cells with Rituximab improves clinical responses in RA patients, this treatment strategy leaves patients susceptible to infections. Here we use of Siglec-engaging Tolerance-inducing Antigenic Liposomes (STALs) to selectively target the citrulline-specific B-cells. ACPA production from purified human RA patients’ B-cells in vitro was achieved through a set of stimulation conditions, which includes the following: BAFF, anti-CD40, IL-21, and LPS. In vivo generation of citrulline specific B-cells and ACPA production was accomplished by antigenic liposomes consisting of monophosphoryl lipid A (MPLA) and a cyclic citrullinated peptide (CCP) administered to SJL/J mice. We show that STALs that codisplay a high affinity CD22 glycan ligand and synthetic citrullinated antigen (CCP STALs) can prevent ACPA production from RA patients’ memory B-cells in vitro. These CCP STALs were also effective in inducing tolerance to citrullinated antigens in SJL/J mice. The results demonstrate that tolerization of the B-cells responsible for ACPA can be achieved by exploiting the inhibitory receptor CD22 with high-affinity glycan ligands. Such a treatment strategy could be beneficial in the treatment of RA." @default.
• W2919086883 created "2019-03-11" @default.
• W2919086883 creator A5010159987 @default.
• W2919086883 creator A5021346095 @default.
• W2919086883 creator A5022981941 @default.
• W2919086883 creator A5027112759 @default.
• W2919086883 creator A5039824850 @default.
• W2919086883 creator A5087354201 @default.
• W2919086883 date "2019-03-05" @default.
• W2919086883 modified "2023-10-13" @default.
• W2919086883 title "Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis" @default.
• W2919086883 cites W1530838758 @default.
• W2919086883 cites W1534043095 @default.
• W2919086883 cites W1544472757 @default.
• W2919086883 cites W1554023045 @default.
• W2919086883 cites W1569731252 @default.
• W2919086883 cites W1582204239 @default.
• W2919086883 cites W1922855985 @default.
• W2919086883 cites W1964042179 @default.
• W2919086883 cites W1964890547 @default.
• W2919086883 cites W1974718865 @default.
• W2919086883 cites W1977195099 @default.
• W2919086883 cites W1979510976 @default.
• W2919086883 cites W1988145586 @default.
• W2919086883 cites W1988267027 @default.
• W2919086883 cites W1992988295 @default.
• W2919086883 cites W1998612840 @default.
• W2919086883 cites W2004208265 @default.
• W2919086883 cites W2005201039 @default.
• W2919086883 cites W2005699747 @default.
• W2919086883 cites W2009103286 @default.
• W2919086883 cites W2010461377 @default.
• W2919086883 cites W2013573826 @default.
• W2919086883 cites W2015215846 @default.
• W2919086883 cites W2017958390 @default.
• W2919086883 cites W2020966190 @default.
• W2919086883 cites W2022039920 @default.
• W2919086883 cites W2023442831 @default.
• W2919086883 cites W2024988150 @default.
• W2919086883 cites W2034839671 @default.
• W2919086883 cites W2034949980 @default.
• W2919086883 cites W2052360985 @default.
• W2919086883 cites W2065210931 @default.
• W2919086883 cites W2073831898 @default.
• W2919086883 cites W2077286174 @default.
• W2919086883 cites W2082905896 @default.
• W2919086883 cites W2085192554 @default.
• W2919086883 cites W2086080135 @default.
• W2919086883 cites W2096966555 @default.
• W2919086883 cites W2101840353 @default.
• W2919086883 cites W2102153017 @default.
• W2919086883 cites W2102990692 @default.
• W2919086883 cites W2103007380 @default.
• W2919086883 cites W2104590417 @default.
• W2919086883 cites W2106096425 @default.
• W2919086883 cites W2107005433 @default.
• W2919086883 cites W2109578241 @default.
• W2919086883 cites W2116492370 @default.
• W2919086883 cites W2122000071 @default.
• W2919086883 cites W2122176733 @default.
• W2919086883 cites W2124079316 @default.
• W2919086883 cites W2128222224 @default.
• W2919086883 cites W2128952811 @default.
• W2919086883 cites W2129840266 @default.
• W2919086883 cites W2132841358 @default.
• W2919086883 cites W2133964489 @default.
• W2919086883 cites W2139998405 @default.
• W2919086883 cites W2141522272 @default.
• W2919086883 cites W2145322488 @default.
• W2919086883 cites W2149266658 @default.
• W2919086883 cites W2150111051 @default.
• W2919086883 cites W2152348310 @default.
• W2919086883 cites W2157231562 @default.
• W2919086883 cites W2158434979 @default.
• W2919086883 cites W2158637536 @default.
• W2919086883 cites W2164744416 @default.
• W2919086883 cites W2165528840 @default.
• W2919086883 cites W2165574508 @default.
• W2919086883 cites W2166732840 @default.
• W2919086883 cites W2177851274 @default.
• W2919086883 cites W2265492985 @default.
• W2919086883 cites W2269217719 @default.
• W2919086883 cites W2325183941 @default.
• W2919086883 cites W2404262996 @default.
• W2919086883 cites W2511881100 @default.
• W2919086883 cites W2560381583 @default.
• W2919086883 cites W2579987967 @default.
• W2919086883 cites W2582017063 @default.
• W2919086883 cites W2735687492 @default.
• W2919086883 cites W291686492 @default.
• W2919086883 cites W4210968471 @default.
• W2919086883 cites W4236183098 @default.
• W2919086883 doi "https://doi.org/10.1021/acschembio.8b01018" @default.
• W2919086883 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6941425" @default.
• W2919086883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30835424" @default.
• W2919086883 hasPublicationYear "2019" @default.
• W2919086883 type Work @default.
• W2919086883 sameAs 2919086883 @default.

• next